← All science articles

· 2 min read

Defibrotide Boosts Prostacyclin Release and Aids Kidney Recovery in Rabbits

By Kristense at Havdis AI Science Team, approved by Andreas Lyhammer

Havdis Arctic PDRN95c against a stormy Norwegian coastline

Based on the PubMed abstract — the full text of this paper was not freely available.

Berti and colleagues, writing in Eicosanoids in 1991, studied defibrotide, a single-stranded polydeoxyribonucleotide (a chain of DNA building blocks), in rabbits to see how it affects blood vessel signaling and kidney injury caused by interrupted blood flow.

Using isolated, perfused rabbit kidneys, the researchers found that defibrotide triggered a dose-dependent release of prostacyclin, a hormone-like molecule that affects blood vessel dilation and platelet clumping; at the highest dose tested (500 micrograms per milliliter per minute) the release rose roughly fourfold, and this effect was blocked by a drug called indomethacin. In live rabbits given defibrotide intravenously (50 mg/kg), blood leaving the kidneys showed less platelet activation than in untreated animals, pointing to ongoing prostacyclin release that lasted longer than the drug's measured presence in blood would predict.

In a separate experiment, the team blocked rabbits' renal arteries for 30 minutes to mimic a loss-of-blood-flow injury, then restored flow. Kidney filtration dropped by about 50% in untreated animals during the first hour and barely recovered after four hours. Defibrotide, given as a bolus plus continuous infusion, did not prevent the initial drop but allowed full recovery by the end of the observation period, while indomethacin worsened the injury.

This is laboratory and animal-model work only; it does not establish effects in humans or any skin or cosmetic application.

Our reflection

This 1991 study is part of the deeper pharmacological record on polydeoxyribonucleotides, showing early evidence that these DNA fragments can influence vascular signaling molecules like prostacyclin in animal kidneys. It sits far from today's skin and tissue-repair applications, but it is one of the data points that helped establish polydeoxyribonucleotides as biologically active molecules worth studying. At Havdis, we see this long research history as part of the foundation the field continues to build on.

Source

Berti F, Rossoni G, Bianchi G, Alberico P, Tettamanti R, Calvani AB et al. (1991). Eicosanoids.

Read the paper on PubMed

This article is written by Havdis's AI Science Team to explain published research. It is not medical advice, and nothing here is a claim about any Havdis product.

From research to ingredient

Developing with PDRN? Let’s talk.